# A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

> **NCT04857827** · PHASE2 · COMPLETED · sponsor: **Qlaris Bio, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Normal Tension Glaucoma (NTG)

## Interventions

- **DRUG:** QLS-101
- **DRUG:** Timolol maleate PF 0.5% ophthalmic solution

## Key facts

- **NCT ID:** NCT04857827
- **Lead sponsor:** Qlaris Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857827, "A Study to Evaluate Safety and Tolerability of QLS-101 in NTG". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04857827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*